RxDoctor Payments Data

Tawhid Hossain, MD

Ophthalmology · St Augustine, FLNPI 1164508354

Payments from drug & device makers

$1,300in general payments, 2019–2025

Across 56 payments — averaging $23.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$755
  • Bausch & Lomb Americas Inc.$137
  • Alcon$127
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$81
  • Dompe US, Inc.$63
  • Eyevance Pharmaceuticals LLC$62
  • plus $74 from 4 others

What the payments were for

  • Food & beverage$1,300100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,300 in reported general payments places this provider in the 35th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$134,401
Medicare patients
417
Services billed
1,618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost130$45,549
RestasisCyclosporine42$27,219
TyrvayaVarenicline Tartrate21$13,067
SimbrinzaBrinzolamide/Brimonidine Tart26$8,618
CombiganBrimonidine Tartrate/Timolol25$6,801
RhopressaNetarsudil Mesylate13$4,125
Tobramycin-DexamethasoneTobramycin/Dexamethasone75$2,773
Latanoprost214$1,997
Loteprednol Etabonate12$1,894
Brinzolamide11$1,355
Brimonidine Tartrate33$666
Dorzolamide Hcl21$641
Atropine Sulfate11$202
Timolol Maleate21$124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$755$79,569197 claims
Oyster Point Pharma, Inc.Tyrvaya$24$13,06721 claims
AlconSimbrinza$127$8,61826 claims
Aerie Pharmaceuticals, Inc.Rhopressa$17$4,12513 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$81$1,89412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in St Augustine

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →